Lithostat (Acetohydroxamic Acid) Patent Expiration, LOE Window & CMS Spending

Lithostat (Acetohydroxamic Acid) by Mission Pharmacal: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $800K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMission Pharmacal
FDA Application & PathwayN018749 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$800K
2024 Medicare Part D Spend$651K
2024 Medicaid Spend$149K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel